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Abstract
Purpose Laboratory studies have suggested that statins may
have useful anti-cancer effects against Barrett’s epithelial can-
cer lines. A variety of effects have been reported in clinical
studies.
Methods We performed a systematic review and meta-
analysis of the association between statin use and the devel-
opment of oesophageal cancer. Multiple databases were
searched for studies reporting the association of statin use
and oesophageal cancer. Meta-analysis on the relationship be-
tween statin use and cancer incidence was performed.
Results Twenty publications met eligibility criteria, yielding
22 datasets for meta-analysis. All were observational studies.
Population-level studies included 372,206 cancer cases and
6,086,906 controls. Studies examining adenocarcinoma de-
velopment in Barrett’s oesophagus included 1057 cancers
and 17,741 controls. In patients with Barrett’s oesophagus,
statin use was associated with a reduced incidence of adeno-
carcinoma (pooled adjusted odds ratio (OR) 0.59 (95% confi-
dence intervals 0.50–0.68)), with no heterogeneity between 11
studies. Population-based studies demonstrated more hetero-
geneity but showed that statin use was associated with a lower
incidence of both oesophageal adenocarcinoma (OR 0.57
(0.43–0.76)) and all oesophageal cancers (OR 0.82 (0.7–
0.88)). Information on statin type, dose, and duration was
reported too infrequently for statistical analysis but individual
studies showed a tendency to a dose- and duration-dependant
decrease in cancer incidence.
Conclusions Statin use is associatedwith a significantly lower
incidence of oesophageal adenocarcinoma. This is seen in
both Barrett’s cohorts and general populations. Further studies
should focus on drug, dose, and duration and the interaction
with other risk and preventative factors.
Keywords Barrett’s oeosphagus . Chemoprevention . Cancer
risk . Oesophageal carcinoma . Statins
Abbreviations
aOR Adjusted odds ratio
BO Barrett’s oesophagus
CI Confidence interval
OAC Oesophageal adenocarcinoma
OGJA Oesophagogastric junction adenocarcinoma
OSC Oesophageal squamous cancer
NSAID Non-steroidal anti-inflammatory drug
OR Odds ratio
Introduction
Oesophageal carcinoma (OC) affects 450,000 people
worldwide and is the sixth leading cause of cancer-related
mortality in the world [1]. The two most common histo-
logical subtypes, squamous cell carcinoma (OSC) and ad-
enocarcinoma (OAC), together make up approximately
98% of this number. Global epidemiological studies show
that whilst global incidence of OSC is greater than OAC,
the incidence of OAC is now greater than OSC in the
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developed countries of the West such as the UK, the
Netherlands, and the USA [2, 3]. Currently, prognosis for
oesophageal cancer remains one of the poorest amongst all
cancers, with 5-year survival rates around 15% [3, 4]. This
is largely due to the proportion of patients presenting at
advanced disease stages. In OAC in particular, this has
led to management strategies revolving around monitoring
risk factors, most important being Barrett’s oesophagus
(BO). To this effect, endoscopic surveillance as well as
ablative procedure, principally radiofrequency ablation
(RFA), has been developed [5]. Although surveillance
and intervention strategies do seem to reduce the incidence
of OAC, RFA is not without costs and complications [5].
However, due to the generally asymptomatic nature of
BO, most cases of OAC arise outside surveillance pro-
grams. This is an area where chemopreventative strategies
could make a difference to the general population. In the
past 10 years, experimental evidence has shown that
statins [hydroxymethlyglutaryl-CoA reductase inhibitors
(HMG-CoA inhibitors)] could potentially play a role in
reducing progression of BO to OAC [6, 7]. The mecha-
nisms proposed include upregulation of pro-apoptotic pro-
teins such Bad and Bax, as well as reduced cell prolifer-
ation and enhanced apoptosis through reduced activation
of signalling G-proteins as a consequence of reduced
levels of melavonate due to inhibition of the HMG-CoA
reductase [6, 7]. Through these mechanisms and possibly
other mechanisms, statins attenuate the malignant behav-
iour of OAC cell lines [6–10]. Evidence from a variety of
clinical studies supports this hypothesis. Four years ago,
two separate meta-analyses using slightly different
methods came to almost identical conclusions: statin use
was associated with a significant 43% reduction in the
incidence of OAC in Barrett’s cohorts and a smaller
[19%] reduction in the incidence of all oesophageal can-
cers in population studies [11, 12]. However, these studies
highlighted areas of lack of information including the pre-
cision of the inverse association with statin use, effects of
confounding risk factors, and effects in different popula-
tions. Since the publication of these meta-analyses, mul-
tiple additional studies have been published and we have
performed an updated systematic review and meta-
analysis examining the association between statin use
and OAC with the aim of further refining the association
and in particular defining knowledge gaps that could be
beneficially be the target of future studies [12]. The inclu-
sion of more recent data has enabled us to specifically
examine the association between statin use and oesopha-
geal cancer in three categories: statin use in relation to
malignant progression to OAC in Barrett’s oesophagus
cohorts, the association between statin usage and OAC
in a population cohorts, and the association between statin
usage and all oesophageal cancers on a population scale.
Methods
This systematic review was performed according to the
Preferred Reporting Items for Systematic reviews and Meta-
Analyses Guidelines (PRISMA guidelines) and as previously
described [12, 13].
Selection Criteria
Eligible study design characteristics included randomised
controlled trials, observational studies (cohort and case-
control design) that met the following inclusion criteria: statin
exposure status with reliable evidence through record linkage
or otherwise, reported disease incidence (oesophageal
adenoncarcinoma or high-grade dysplasia, or oesophageal
cancer), and provision of hazard ratio (HR), odds ratio (OR),
or relative risk (RR), and in the case of their absence, provi-
sion of data for their calculation.
Data Sources and Search Strategy
A systematic literature search of Medline, Embase, Web of
Science, Cochrane database, andGoogle Scholar from inception
until 4th February 2017 was performed in order to identify all
relevant studies that investigated oesophageal cancer incidence
in statin users. A combination of keywords and medical subject
heading terms were used including Boesophageal neoplasm^,
BBarrett’s oesophagus^, Boesophageal adenocarcinoma^,
Bstatin^, and Bhydroxymethylglutaryl-CoA reductase inhibitor .^
Two investigators (Thomas T, Beales ILP) then independently
reviewed and excluded articles that were not relevant to the
research topic. A manual search of reference lists as well as
relevant review articles was undertaken to screen for potential
articles.
Data Extraction and Quality Assessment
Data was extracted from the selected studies into a
standardised table by the two chief investigators. This table
is provided in Table 1. Data was organised into the three
subgroups being examined. Information regarding duration
and dose of statin use was also extracted alongside number
of statin/non-statin users to further assess the impact of statins.
Unadjusted and adjusted risk ratios were also extracted where
available. We checked the validity of the included studies
based on possibility of confounding and potential for misclas-
sification of tumour pathology and/or drug exposure. Risk of
bias assessment was focused on the selection of participants,
comparability of cases and controls (with any adjustments for
confounding), and methods used in ascertaining drug expo-
sure and outcomes. The quality of all studies was assessed
using the Newcastle-Ottawa Quality Assessment Scales by
two investigators independently using the star-rated system
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Table 1 Characteristics of included studies
First author [ref] Location, setting Study design Total
number of
patients
Primary
outcome of
interest
Patient on
statins
Patient not on
statins
Variables
adjusted
for
Newcastle-
Ottawa
score
No.
of
EAC/
EC
cases
No. of
non-
EAC/
EC
cases
No. of
EAC/
EC
cases
No. of
non-
EAC/EC
cases
Nguyen 2010 [14] US; multicentre,
hospital-based
Retrospective
cohort
344 patients
OAC 33
Incidence
of OAC
in
Barrett’s
cohort
6 63 27 188 1, 2, 7, 9 8a
Nguyen 2009 [15] US; multicentre,
hospital-based
Nested case
control
812 patients
OAC 116,
BO 696
Incidence
of OAC
in
Barrett’s
cohort
41 336 75 360 1, 2, 3 9a
Kastelein [16] The Netherlands;
multicentre,
hospital-based
Prospective
cohort
570 patients
HGD/OAC
38
Incidence
of
OACC in
Barrett’s
cohort
9 200 29 332 1, 2, 7, 8,
9
9a
Kantor [17] US; hospital-based Prospective
cohort
411 patients
OAC 56
Incidence
of OAC
in
Barrett’s
cohort
6 50 50 305 1, 2, 4, 9 9a
Beales 2012a [18] UK; hospital-based Case control 255 patients
OAC 85, BO
170
Incidence
of OAC
in
Barrett’s
cohort
17 60 68 110 1, 2, 4, 5,
6, 8
8a
Krishnamoorthi [19] US;
population-based
Cohort 9660 patients
OAC 103
Incidence
of OAC
in
Barrett’s
cohort
NR NR NR NR 1, 2, 4, 6,
9
8a
Iyer [20] UK;
population-based
Cohort NR Incidence
of OAC
in
Barrett’s
cohort
NR NR NR NR NR 6a
Agrawal [21] US; hospital-based Case control 583 patients Incidence
of OAC
in
Barrett’s
cohort
55 307 60 161 1, 4, 5, 6,
9
7a
Masclee [22] UK and the
Netherlands;
multicentre,
population-based
Nested case
control
777 patients
OAC 45, BO
732
Incidence
of OAC
in
Barrett’s
cohort
12 253 33 479 None
listed
7a
Cooper [23] UK;
population-based
Nested case
control
3749 patients
OAC 55
Incidence
of OAC
in
Barrett’s
cohort
18 1124 37 2570 1, 2, 4 8a
Nguyen 2015 [24] US;
population-based
Nested case
control
1167 patients
OAC 311,
BO 856
Incidence
of OAC
in
Barrett’s
cohort
125 462 186 394 1, 4, 6, 9 9a
Kaye [25] UK;
population-based
Case control 530 patients
OC 100,
control
Incidence
of any
OC in
9 34 91 396 1, 2, 4, 6 8a
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Table 1 (continued)
First author [ref] Location, setting Study design Total
number of
patients
Primary
outcome of
interest
Patient on
statins
Patient not on
statins
Variables
adjusted
for
Newcastle-
Ottawa
score
No.
of
EAC/
EC
cases
No. of
non-
EAC/
EC
cases
No. of
EAC/
EC
cases
No. of
non-
EAC/EC
cases
430 popula-
tion
Friedman [26] US;
population-based
Cohort 4,413,100
patients
Incidence
of any
OC in
popula-
tion
68 762 361,802 4,050,468 NR 9a
Hippiseley-Cox
[27]
Male UK;
population-based
Cohort 989,729, OC
1225
Incidence
of any
OC in
popula-
tion
216 120,866 1009 867,638 1, 4, 6 9a
Female UK;
population-based
Cohort 1,013,565,
OC 584
Incidence
of any
OC in
popula-
tion
78 104,670 506 908,311 1, 4, 6 9a
Vinogradava [28] UK;
population-based
Nested case
control
16,200
patients
OC 3159,
control
13,041
Incidence
of any
OC in
popula-
tion
496 2106 2663 10,935 4, 6 9a
Bhutta [29] (abstract) UK;
population-based
Prospective
cohort
18,484
patients
OAC 581,
OSC 322
Incidence
of any
OC in
popula-
tion
615 2539 3101 12,229 NR 7a
Lai [30] Taiwan;
population-based
Case control 2745 patients
OC 549,
control
2196
Incidence
of any
OC in
popula-
tion
49 238 500 1958 1, 2, 8, 9 6a
Chan [31] Taiwan;
population-based
Case control 985 patients
OC 197,
control
788
Incidence
of any
OC in
popula-
tion
29 131 168 657 8, 9 7a
Alexandre [32] EAC UK;
population-based
Nested case
control
OAC 581
Control 2167
Incidence
of OAC
in
popula-
tion
60 222 521 1945 4, 6, 9 8a
EGJA OAC 213
Control 783
Incidence
of OAC
in
popula-
tion
20 79 193 704 4, 6, 9 8a
Beales 2012b [33] UK; hospital-based Case control 560 patients
OAC 112,
control
448
Incidence
of OAC
in
popula-
tion
19 158 93 290 1, 2, 4, 5,
6, 9
8a
Variables adjusted for (1) age, (2) sex, (3) race, (4) smoking, (5) alcohol use, (6) obesity, (7) BO length, (8) oesophagitis or reflux symptoms, (9)
medications (NSAIDs/aspirin)
NR not reported
a Statin use at baseline and not during course of study
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as previously described [12, 34]. Any discrepancies in scoring
were then resolved through combined reassessment and con-
sensus by all authors. The final quality assessment scores are
listed in Table 1.
Outcomes Assessed
The primary analysis examined the association of statin and
the incidence of oesophageal carcinoma as well as oesopha-
geal adenocarcinoma specifically, through comparison of
users and non-users. Subgroup analyses were used to investi-
gate this further. Three categories were devised according to
study cohort characteristics. These includedOAC incidence in
a population cohort, OAC incidence in Barrett’s oesophagus
cohort, and incidence of all oesophageal cancers in a popula-
tion cohort. Secondary analysis was focussed on examining
these studies for any potential duration or dose relationship
between statin and cancer incidence. In order to perform this,
we limited analyses on duration or dose to studies that explic-
itly provided reliable statin use description data.
Statistical Analysis
Review Manager (Revman) version 5.3 (Nordic Cochrane
Center, Copenhagen, Denmark) was used to calculate the
pooled risk ratio (compiling ORs or HR from individual stud-
ies) using the inverse variance method, random effects model
as previously described [12]. Due to the relative rarity of out-
comes, ORwere considered as approximations of HR and RR.
Analysis was carried out on unadjusted as well as adjusted risk
ratios. Statistical heterogeneity was assessed using the
Cochrane I2 statistic, with I2 > 25% indicating moderate sta-
tistical heterogeneity and I2 > 50% indicating a substantial
level of heterogeneity. A sensitivity analysis was performed
by separately omitting one study at a time to assess if the
pooled estimate had changed significantly compared to the
results of all pooled studies.
Results
The search strategy identified 110 individual potentially
suitable publications. Through the eligibility and screen-
ing processes, a total of 20 publications were included in
the meta-analysis [14–33]. This totalled 22 different rele-
vant studies as two publications reported separate data
and adjusted odds ratios for different cohorts (either sep-
arate data for males and females or separate histological
subtype of oesophageal cancer) [27, 32] (Fig. 1). All stud-
ies were published in English. The studies identified were
clearly split into three categories based upon the specific
population being examined: the association between statin
use in the community and incidence of OAC, the
relationship between statin use in a BO cohort on OAC
rates, and the association with all oesophageal cancer on a
population scale. Table 1 lists the studies included and
their important characteristics. Two of the included stud-
ies were only published in abstract format; however, suf-
ficient relevant information necessary for analysis was
extracted from them [20, 29]. The other studies were in
full peer-reviewed format.
For each planned subgroup analyses, separate meta-
analyses were conducted on adjusted and unadjusted data.
This was due to the heterogeneity in presentation of risk factor
adjustment in the studies being analysed. As in the previous
meta-analysis [12], heterogeneity in the reporting of statin
dose and duration meant statistical analysis of this data would
not be feasible.
Characteristics of Included Studies
Twenty-two datasets reported on a total of 373,263 cases and
6,105,704 controls. As a proportion, 3.7% of the total popu-
lation were statin users. Of 236,608 statin users, approximate-
ly 0.82% developed HGD/OC. Of 6,231,642 non-statin users,
5.90% developed HGD/OC. Details of the included studies
are given in Table 1. The studies were from a variety of geo-
graphic locations with five from the USA and seven from the
UK. No randomised control trials were identified during the
search and in total, data were available from eight cohort, six
nested case-control, and six case-control studies The majority
of outcome assessments in nested case-control studies [23, 24,
32] and cohort study [19] were done through record linkage.
Two case-control studies [18, 33] ascertained exposure
through the use of structured interviewers where participants
were not completely blind to case-control status. One case-
control study analysed exposure through the use of secure
records (i.e. medical notes). Eleven studies [14–24] examined
statin use and the incidence of OAC in Barrett’s cohort. Eight
datasets reported [25–31] the impact of statins on incidence of
any OC in population and two studies (with a total of 3
datasets [32, 33]) looked at the relationship between statins
and OAC in the general population.
Table 2 displays the baseline characteristics of the popula-
tion from each study. Mean age at BO diagnosis or age of
control in nested case-control studies ranged from 60.7 to
70.9 years. In case-control studies, the mean age of diagnosis
of OC ranged from 60.9 to 70.7 years. With the exception of
one study [32], the proportion of men as part of study popu-
lation exceeded 60%. Length of BO was only reported in two
studies [15, 16]. Three studies reported rates of reflux symp-
toms and endoscopic oesophagitis [16, 22, 31]. Statin use in
the included study populations ranged from 13 to 54%. Proton
pump inhibitors (PPI) used in the study populations ranged
from 51 to 94%.
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Quality Assessment
The studies included in the meta-analysis were ranked as be-
ing medium (11) to high quality (11) with the exception of two
studies [20, 30]. A more detailed breakdown of study quality
assessment can be found in Table 1. Baseline characteristics in
patients are relatively consistent across studies producing an
appropriate pooled population for oesophageal carcinoma.
This was a population consisting of a majority Caucasian male
population of age greater than 60 years. Overall 13 studies
inc luded ad jus t ed fo r concomi t an t po t en t i a l l y
chemopreventative medication in the form of aspirin/non-
steroidal anti-inflammatory drugs (NSAIDs). The majority
of studies also adjusted for two other main risk factors in-
volved in the development of OC: smoking and obesity.
However, adjustment for other risk factors was variable be-
tween studies. Due to the variability in correcting for and
reporting potential confounders, the pooled data for both un-
adjusted and adjusted odds ratios were separately analysed.
Statin Use in Barrett’s Cohorts Progressing
to Adenocarcinoma
A total of 11 studies were included within this analysis. This
included five cohort studies, two case-control studies, and
four-nested case-control studies. The total sample included a
minimum of 1057 cancer/HGD cases and 17,741 controls
with non-cancerous with BO (the actual numbers included in
one study are not available [20]). All studies adjusted for age
and gender except for one study that did not adjust for gender
[24]. Three studies adjusted for race [14, 16, 18]. Six studies
adjusted for smoking [17–19, 23, 24, 33]. Only one study
adjusted for alcohol use [18]. Four studies adjusted for obesity
[17–19, 24]. Two studies adjusted for length of BO [15, 16]
and reported reflux with/without endoscopic oesophagitis [16,
18]. Five studies adjusted for concomitant medication use
(specifically NSAID/aspirin use) [14–16, 18, 22]. One study
[15] did not report adjusted OR in the final publication and
hence was not included in the relevant meta-analysis
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examining adjusted data. One study [19] used a time-varying
model to assess HR. This was used to give a more reliable
estimate, as it will take into account the time windows when
the patients are taking or not taking statins. This study was
incorporated into the adjusted OR model.
The pooled unadjusted data showed a significant inverse
association between statin use and the incidence of OAC in
Barrett’s cohorts (pooled OR 0.54 (95% CI 0.46 to 0.63))
(P < 0.0001, I2 = 0%) (Fig. 2). This confirmed the pooled
adjusted ORs (OR 0.59 (95% CI 0.50 to 0.68))
(P < 0.00001, I2 = 0%) (Fig. 3). There was no significant
heterogeneity in the studies and sensitivity analyses showed
that the omission of any single study had no effect on the
overall results. Both case-control and cohort studies produced
very similar results and the results of the study only presented
in abstract form for which less detail is available were consis-
tent with all the other studies [20].
There was major variation in the reporting of duration and
dose of statin use within the included studies. This outcome
was therefore unsuitable for statistical analysis. Nguyen et al.
[14] suggested that duration of statin use greater than 1 year
was associated with a reduced incidence of OAC (aOR 0.52;
95% CI 0.3 to 0.91). Beales et al. [22] reported that statin use
of greater than 5 years was associated with a reduced inci-
dence of OAC (aOR 0.41; 95% CI 0.15 to 0.85). Nguyen
et al. [24] also reinforced this general finding with both unad-
justed and adjusted OR for the period of 6 to 18 months show-
ing a reduced incidence of OAC (OR 0.41; 95% CI 0.26 to
0.63, and aOR 0.52; 95% CI 0.32 to 0.85). Although other
ORs within this study [24] showed efficacy at less than
6 months and greater than 18 months, these ORs were not
statistically significant after adjusting for confounders and po-
tential risk factors. In terms of dosage, Beales et al. [18] re-
ported that statin dose above 40 mg equivalent of simvastatin
was associated with a more pronounced inverse association
than doses below 40 mg simvastatin dose equivalents (adjust-
ed OR 0.31; 95% CI 0.05 to 0.97 compared to 0.59; 95% CI
0.27 to 0.98, respectively). The other studies did not provide
data on statin dose, type, or duration.
Statin Use in Population Cohort Progressing
to Adenocarcinoma
This subgroup analysis consisted of data extracted from two
publications. One paper reported separate data from OAC and
oesophagogastric junction adenocarcinoma (OGJA); due to
the potential difference in biology, these were analysed and
reported separately [32]. All studies were case-control studies.
The total sample size was 4305 patients. This consisted of 907
cases of OAC with 3398 controls. All studies included adjust-
ed and unadjusted data, and hence, both sets of data were
compiled into the meta-analysis. Alexandre et al. [32] adjusted
for risk factors such as smoking, obesity, and concomitantTa
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medication use in the form of NSAIDs, aspirin, and PPIs.
Beales et al. [33] adjusted for age, gender, smoking, alcohol,
obesity, and medications.
Pooled unadjusted ORs showed a non-significant associa-
tion with wide confidence intervals with significant heteroge-
neity (0.73 (0.41–1.32)) (I2 = 81%) (Fig. 4). However, the
meta-analysis of pooled adjusted data (Fig. 5) showed a sig-
nificant negative association between statin use and OAC in-
cidence (OR 0.57; 95% CI 0.43 to 0.76) (P < 0.001), with no
significant heterogeneity between studies (I2 = 0%).
When examining duration of statin use, Beales et al. [33]
showed duration of use greater than 5 years had greater in-
verse association (adjusted OR 0.29; 95% CI 0.1 to 0.67)
compared to other time periods such as 2 to 5 years (adjusted
OR 0.51; 95% CI 0.19 to 0.97). Both studies [32, 33] exam-
ined dose with a common dose margin of 40 mg simvastatin.
Beales et al. [33] reported that doses greater than 40 mg sim-
vastatin were associated with a greater reduction in risk (ad-
justed OR 0.16; 95% CI 0.05 to 0.6) than doses less than
40 mg (adjusted OR 0.53; 95% CI 0.25 to 0.86). Although
the data provided for statin dose less than 40 mg in Alexandre
et al. [32] are not statistically significant, the statin dose for
greater than 40 mg shows a substantial reduction in risk of
OAC in a population cohort (adjusted OR 0.51; 95% CI 0.27
to 0.96).
Statin use in Population Cohort Progressing
to Oesophageal Cancer (All Types)
This subgroup analysis examined the potential effect of statins
on the incidence of all types of oesophageal carcinomas in
population cohorts. A total of eight cohorts were used in this
analysis. This consisted of seven studies with one study [27]
providing two populations consisting of the male and female
population analysed separately. The sample size totalled
6,455,338 patients. There were 371,400 cases of oesophageal
carcinomas in a background of 6,083,938 patients from pop-
ulation cohorts. Three studies adjusted for age [25, 27, 30],
smoking [25, 27, 28], and obesity [25, 27, 28]. Two studies
adjusted for gender [25, 30]. Lai et al. [30] and Chan et al. [31]
both adjusted for symptomatic reflux and endoscopic
oesophagitis along with concomitant use of medications (as-
pirin/NSAIDs). One study [26] did not provide details of any
Fig. 2 Meta-analysis of pooled unadjusted odds ratios for the effect of statin use on the development of oesophageal adenocarcinoma in patients with
Barrett’s oesophagus
Fig. 3 Meta-analysis of pooled adjusted odds ratios for the effect of statin use on the development of oesophageal adenocarcinoma in patients with
Barrett’s oesophagus
J Gastrointest Canc
adjustment in both study design and, statistically, hence was
unable to be included in the adjusted OR meta-analysis.
The result of the meta-analysis of unadjusted odds ratios
(1.07 (0.90–1.26)) (Fig. 6) was statistically insignificant. This
was largely due to the influence of two studies [27, 25]. The
unadjusted and adjusted ORs within the study by Hippiseley
Cox et al. [27] were considerably different. There was sub-
stantial heterogeneity in the pooled unadjusted data (I2 levels
82%). The pooled analysis of adjusted ORs demonstrated that
the use of statins in a population cohort was associated with a
significantly lower incidence of all oesophagus (OR 0.82;
95% CI 0.76 to 0.88) (P < 0.00001) with no heterogeneity
in the data (I2 = 0%) (Fig. 7). Sensitivity testing showed that
the significance of the result was not influence by the exclu-
sion of any single study.
Similar to the previous analysis, there was significant het-
erogeneity in the methods of data collection and reporting
regarding duration and dosage of statins. This rendered statis-
tical analysis inappropriate. Friedman et al. [26] actually re-
ported statins were associated with an increased risk of OC in
the male population (adjusted OR 1.7; 95% CI 1.05 to 2.75).
However, with such large confidence intervals in place, this
data are potentially unreliable. Data from Lai et al. [30]
showed that statins were associated with a reduced incidence
of OAC in a population cohort particularly when used for
greater than 12 months (adjusted OR 0.14; 95% CI 0.04 to
0.56). In terms of statin doses, only Hippiseley-Cox et al. [27]
provided detailed information. In males, doses of simvastatin
equivalent to 40–80 mg showed an aOR 0.66; 95% CI 0.48 to
0.91 with the incidence of all oesophageal cancers. Doses of
10 mg atorvastatin were associated with reduced incidence of
OC (aOR 0.68; 95% CI 0.49 to 0.95). In females, this trend
was reversed with data suggesting dosages of 10 mg atorva-
statin (aOR 0.67; 95% CI 0.49 to 0.95) were more effective in
reducing OC rates in a population cohort than 40–80 g sim-
vastatin (aOR 0.82; 95% CI 0.66 to 0.91).
Discussion
The primary objective of this meta-analysis was to examine
association of statins with the development of oesophageal
cancers, particularly oesophageal adenocarcinoma. Our
pooled estimates show that statins have a strong association
with a reduction in the risk of OAC (approximately 41% re-
duction of risk) particularly when used in patients with pre-
existing Barrett’s oesophagus. The adjusted data from 11 stud-
ies provides a reasonably narrow confidence interval for this
figure. These data are similar to those reported in the previous
meta-analyses: Singh et al. [11] and Beales et al. [12] adjusted
OR = 0.59; 95% CI, 0.45–0.78 and adjusted OR = 0.57; 95%
CI, 0.43–0.75, respectively. The current updated meta-
analysis has more than doubled the number of studies includ-
ed (from 5 to 11) and increased the number of OAC cases 3-
fold (317 to 1057), and this inclusion of additional studies has
allowed a much tighter definition of the likely margin of as-
sociation with much smaller confidence intervals.
A similar degree of reduction in OAC was associated with
statin use in population cohorts. The pooled adjusted odds
ratios showed a reduction of 43% in OAC incidence.
However, with only three datasets included, it is relatively
the most underpowered of all analyses included in this study.
However, this is a new finding; previous systematic reviews
did not allow statistical analysis of this particular subgroup.
Fig. 4 Meta-analysis of pooled unadjusted odds ratios for the effect of statin use on the development of oesophageal adenocarcinoma in population-
based studies
Fig. 5 Meta-analysis of pooled adjusted odds ratios for the effect of statin use on the development of oesophageal adenocarcinoma in population-based
studies
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Further studies are warranted to investigate this effect more
thoroughly especially in light of the rising incidence rates of
OAC. It is notable that this subgroup analysis included a spe-
cific oesophagogastric junction adenocarcinoma group, whilst
there may be some important biological differences between
this and more classical OAC [8], it was felt appropriate to
include this cohort as the majority of the other studies included
in this systematic review included junctional cancers within
the cancer cases, making no distinction between the OAC and
OGJA for statistical analysis. Two studies [18, 33] specifically
excluded Siewert III OGJA cancer.
It remains an area of active research whether statins have
beneficial anti-cancer effects merely on progression of non-
dysplastic BO or whether they are actually associated with a
reduction in the development of BO itself. Whilst most of the
in vitro studies have examined the effects of statins on various
models of Barrett’s oesophagus, recent data including a meta-
analysis have reported that statin use is associated with a re-
duced incidence Barrett’s oesophagus [35].
Statin use in the population is associated with a reduced
incidence (by 18%) of all types of oesophageal cancers.
Again, three of the major studies [27–29] included in the anal-
ysis provided very consistent data in describing this effect.
The previous meta-analysis [12] suggested very similar reduc-
tion of risk at OR = 0.81; 95% CI 0.75–0.88. There was much
more heterogeneity in the unadjusted results examining statin
use at the population level and all oesophageal cancers than in
the other analyses. The heterogeneity was significantly re-
duced when comparing the odds ratios adjusted for other var-
iables. This probably reflects the wider variety of geographical
and health care locations included in this group (certainly
compared to the more homogeneous secondary care
Barrett’s cohorts) and reinforces the problems with potential
confounding by indications and risk factors in studies at that
population level. Despite this, there were no obvious outlying
studies and the pooled analysis of the adjusted odds ratios
showed no significant heterogeneity.
Most of the published data have examined the relationship
between statins and OAC; there are much less data concerning
squamous cancer. Although there are well-performed labora-
tory studies providing biological plausibility and exploring the
effects of statins on oesophageal adenocarcinoma and non-
malignant Barrett’s cells [6, 7, 10], these corroborating studies
are lacking as regards oesophageal squamous cancer. Given
the contrasting biology and epidemiology between oesopha-
geal adenocarcinoma and squamous cancers, it would not be
surprising if the effect of statins differed between the two. The
relatively smaller apparent protective effect against all oe-
sophageal cancers combined compared to specifically against
OAC may imply that statins have less effect on the
Fig. 7 Meta-analysis of pooled adjusted odds ratios for the effect of statin use on the development of all types of oesophageal carcinoma in population-
based studies
Fig. 6 Meta-analysis of pooled unadjusted odds ratios for the effect of statin use on the development of all types of oesophageal carcinoma in
population-based studies
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development of squamous cancer but further studies are indi-
cated. The relative and absolute numbers of adenocarcinomas
and squamous cancers within the studies examined in this
population-level data meta-analysis are unknown and, given
the disparity of geographical locations studies, are likely to
vary between studies, further contributing to the heterogeneity
of results in this subgroup analysis. We acknowledge that
these population-level, all-oesophagal cancer data are the
weakest and least informative of those specifically included
in this systematic review, but feel these data should be includ-
ed for completeness and to stimulate further research into any
associations between statin use and squamous cancer.
However, the pooled data on all oesophageal cancers are still
consistent with statin use being associated with a lower risk of
oesophageal adenocarcinoma.
Themain limitation to thismeta-analysis is that all included
studies are observational (i.e. cohort or case-control). As such,
regardless of the sample size involved in this study, it is not
completely free of bias and despite the generally high quality
of the observational studies included in this systematic review,
uncorrected bias may still influence the results. However, the
consistency of the results, including lack of heterogeneity,
from different geographical locations, health care systems,
and research methodologies suggests that unadjusted bias is
unlikely to have a major effect on our findings, although it
would be important to establish what the association is be-
tween statin use and cancer risk in relation to specific other
risk factors for OAC such as smoking, obesity, and visceral
obesity [8]. In the adenocarcinoma-specific analysis, particu-
larly in the Barret’s cohorts, the minimal difference between
the pooled adjusted and unadjusted ORs, suggests that con-
founding by indication and residual bias, are unlikely to be
contributing to the results.
It was notable that the number and variety of potential
cofounding variables adjusted varied considerably between
the studies and this would seem to be a major focus for future
work. Despite the evidence that proton pump inhibitors and
NSAIDs [33, 36] are also associated with a reduced incidence
of OAC, not all studies provided data to enable accurate ad-
justment. Laboratory studies and our previous meta-analysis
showed that the combination of statins and cyclo-oxygenase
inhibitors appeared to be additive in both effects on cell lines
[6, 7] and in reducing the incidence of OAC (pooled aOR 0.26
(0.1–0.68)) [12]. However, the more recent studies have not
examined or reported the data to enable further verification of
this association and it is recommended that any further studies
specifically examine this.
Probably the weakest aspect of the current study is the lack
of data on statin type (lipophilic or hydrophilic), dose, drug, or
duration. Previous meta-analyses [11, 12] were similarly lim-
ited in this regard but unfortunately despite the increase in the
number of studies and subjects included in the systematic
review, the data are still inadequate to draw any firm
conclusions. Most studies did not specifically examine this
aspect of statin use and when it was reported, the categories
used were too heterogeneous for statistical analysis. Where
reported there seemed to be a tendency for higher doses and
longer durations to be associated with a lower incidence of
OAC but any future studies should specifically address these
issues.
In conclusion, our updated systematic review and meta-
analysis show that statin use is associated with a significantly
reduced incidence of oesophageal adenocarcinoma in both
Barrett’s cohorts (by 41%) and population-based studies (by
43%). There is also a reduced incidence of all oesophageal
cancers in population-based studies (by 18%), although it is
possible that this is driven mainly through a reduction in the
incidence of OAC rather than OSC; that hypothesis requires
further investigation. The inclusion of additional studies has
enabled much tighter precision of the estimate of the reduction
of OAC associated with statin use in Barrett’s cohorts.
The consistency of the results across multiple studies com-
bined with supportive experimental evidence does suggest
that statins may have useful chemopreventative effects in
Barrett’s oesophagus. Given the relatively low rate of neoplas-
tic progression in BO (approximately 1 in 300 per year [37,
38]), it may not be cost-effective to merely use statins as
chemopreventative agents, but given that the main cause of
death in patients with BO is not oesophageal cancer but vas-
cular diseases, it may be prudent to ensure that statins that are
definitely prescribed to patients with Barrett’s oesophagus
were indicated by vascular risk [39].
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